Aerogen Ltd. and Dance Pharmaceuticals signed a deal to develop an insulin inhalation device for diabetics.

The companies’ planned product would allow millions of diabetics to avoid sticking themselves with needles several times a day to treat the disease with insulin injections.

The device will be designed to administer Dance’s inhaled insulin product using Galway, Ireland-based Aerogen‘s OnQ aerosol generator technology, according to the companies.

The deal gives San Francisco-based Dance an exclusive worldwide license to Aerogen’s technology for insulin delivery, according to the companies. Other terms of the agreement were not disclosed.